Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982629priorityCriticalpatent/ECSP982629A/en
Publication of ECSP982629ApublicationCriticalpatent/ECSP982629A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente invención proporciona proteínas de fusión del virus de papiloma humano (HPV), lígados a un acompañante de fusión inmunológico que proporciona etiopos auxiliares de T al antígeno de HPV. Se prueba que las formulaciones de las vacunas son útiles en el tratamiento o profilaxis de lesiones inducidas por HPV.The present invention provides human papilloma virus (HPV) fusion proteins, linked to an immunological fusion partner that provides T-helper ethiopes to the HPV antigen. Vaccine formulations are proven to be useful in the treatment or prophylaxis of HPV-induced lesions.
ECSP9826291998-08-171998-08-17
FUSION PROTEINS, PROTEIN THAT PROVIDES AUXILIARY EPITOPES OF T AN ANTIGEN OF HUMAN PAPILOMA VIRUSES
ECSP982629A
(en)
Isolated polypeptides based on the neutralizing epitope of the p17 protein from HIV suitable for vaccines as well as neutralizing anti-p17 antibodies that specifically recognize said neutralizing epitope